Cargando…

Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab

BACKGROUND: Indication of omalizumab in the United States was recently extended to include pediatric (6–11 years) uncontrolled moderate-to-severe allergic asthma patients. OBJECTIVE: The purpose of this study was to describe baseline characteristics of this population from a real-world dataset. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kavati, Abhishek, Pilon, Dominic, Ortiz, Benjamin, Paknis, Brandee, Vegesna, Ashok, Schiffman, Bradd, Zhdanava, Maryia, Lefebvre, Patrick, Stone, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028162/ https://www.ncbi.nlm.nih.gov/pubmed/29977648 http://dx.doi.org/10.1177/2152656718763387

Ejemplares similares

Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States
por: Ke, Xuehua, et al.
Publicado: (2018)

Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States
por: Williams, Paul V., et al.
Publicado: (2018)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA
por: Pilon, Dominic, et al.
Publicado: (2022)

Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation
por: Alberts, Mark, et al.
Publicado: (2023)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Venous Thromboembolism Recurrence Among Patients Who Abandon Oral Anticoagulant Therapy in the USA: A Retrospective Longitudinal Study
por: Alberts, Mark, et al.
Publicado: (2023)

Venous thromboembolism recurrence among one-and-done direct oral anticoagulant users: a retrospective longitudinal study
por: Alberts, Mark, et al.
Publicado: (2023)

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey
por: Zhdanava, Maryia, et al.
Publicado: (2022)

Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey
por: Zhdanava, Maryia, et al.
Publicado: (2022)

Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions
por: Zhdanava, Maryia, et al.
Publicado: (2020)

Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug–Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression
por: Zhdanava, Maryia, et al.
Publicado: (2021)

Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021)

Sex, Allergic Diseases and Omalizumab
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA
por: Zhdanava, Maryia, et al.
Publicado: (2021)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Novel treatment of allergic fungal sinusitis using omalizumab
por: Evans, Martin Oman, et al.
Publicado: (2014)

Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
por: Ashkenazi, Moshe, et al.
Publicado: (2018)

Omalizumab is effective in the preseasonal treatment of seasonal allergic rhinitis
por: Zhang, Yuan, et al.
Publicado: (2022)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Women manifest more severe COPD symptoms across the life course
por: DeMeo, Dawn L, et al.
Publicado: (2018)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab
por: Collins, Jennifer, et al.
Publicado: (2012)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Steroid sparing effect of omalizumab in seropositive allergic bronchopulmonary aspergillosis
por: Beam, Keith T., et al.
Publicado: (2015)

Omalizumab in children with severe allergic disease: a case series
por: Crisafulli, Giuseppe, et al.
Publicado: (2019)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis [Erratum]
Publicado: (2018)

Poster 1014: Omalizumab efficiency in patients with allergic rhinitis and chronic sinusitis
por: Gonzalez-Diaz, Sandra Nora, et al.
Publicado: (2014)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
por: Zafari, Zafar, et al.
Publicado: (2018)

Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
por: Nishima, Sankei, et al.
Publicado: (2019)

An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases
por: Liu, Peipei, et al.
Publicado: (2020)

Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study
por: Tang, Rui, et al.
Publicado: (2022)

Omalizumab for the treatment of severe allergic asthma in children: A tale of two
por: Brannick, Sinéad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tqm97v93agdqna4v3hjvj0frk8